HC Wainwright Issues Pessimistic Estimate for AQST Earnings

Aquestive Therapeutics, Inc. (NASDAQ:AQST) – Equities research analysts at HC Wainwright reduced their Q2 2025 earnings per share estimates for shares of Aquestive Therapeutics in a report issued on Wednesday, November 6th. HC Wainwright analyst R. Selvaraju now expects that the company will earn ($0.15) per share for the quarter, down from their previous estimate of ($0.14). HC Wainwright currently has a “Buy” rating and a $10.00 target price on the stock. The consensus estimate for Aquestive Therapeutics’ current full-year earnings is ($0.48) per share. HC Wainwright also issued estimates for Aquestive Therapeutics’ FY2025 earnings at ($0.59) EPS.

AQST has been the subject of several other reports. Leerink Partners lifted their price target on Aquestive Therapeutics from $12.00 to $13.00 and gave the company an “outperform” rating in a research report on Friday, October 25th. JMP Securities restated a “market outperform” rating and issued a $9.00 target price on shares of Aquestive Therapeutics in a research note on Tuesday, October 8th. Six analysts have rated the stock with a buy rating and one has given a strong buy rating to the company’s stock. According to data from MarketBeat.com, the stock presently has an average rating of “Buy” and a consensus target price of $8.83.

Aquestive Therapeutics Trading Up 0.2 %

Aquestive Therapeutics stock opened at $5.08 on Friday. The firm has a 50 day simple moving average of $4.92 and a 200 day simple moving average of $3.84. Aquestive Therapeutics has a 1-year low of $1.55 and a 1-year high of $6.23. The firm has a market capitalization of $462.58 million, a price-to-earnings ratio of -11.29 and a beta of 2.82.

Aquestive Therapeutics (NASDAQ:AQST) last posted its earnings results on Monday, November 4th. The company reported ($0.13) earnings per share for the quarter, missing the consensus estimate of ($0.12) by ($0.01). The firm had revenue of $13.54 million for the quarter, compared to analysts’ expectations of $12.69 million. During the same period last year, the firm earned ($0.03) EPS.

Institutional Trading of Aquestive Therapeutics

Several institutional investors and hedge funds have recently modified their holdings of AQST. Vanguard Group Inc. increased its position in shares of Aquestive Therapeutics by 71.7% in the first quarter. Vanguard Group Inc. now owns 3,242,571 shares of the company’s stock worth $13,813,000 after purchasing an additional 1,353,518 shares during the last quarter. Blue Owl Capital Holdings LP raised its holdings in shares of Aquestive Therapeutics by 30.3% during the 2nd quarter. Blue Owl Capital Holdings LP now owns 1,140,000 shares of the company’s stock valued at $2,964,000 after buying an additional 265,000 shares in the last quarter. Janney Montgomery Scott LLC lifted its position in Aquestive Therapeutics by 4.9% in the 3rd quarter. Janney Montgomery Scott LLC now owns 923,285 shares of the company’s stock worth $4,598,000 after buying an additional 42,800 shares during the last quarter. Bank of New York Mellon Corp bought a new stake in Aquestive Therapeutics in the 2nd quarter worth approximately $594,000. Finally, Deerfield Management Company L.P. Series C purchased a new stake in shares of Aquestive Therapeutics in the 2nd quarter valued at $380,000. Hedge funds and other institutional investors own 32.45% of the company’s stock.

About Aquestive Therapeutics

Aquestive Therapeutics, Inc operates as a pharmaceutical company in the United States and internationally. The company markets Sympazan, an oral soluble film formulation of clobazam for the treatment of lennox-gastaut syndrome; Suboxone, a sublingual film formulation of buprenorphine and naloxone for the treatment of opioid dependence; Zuplenz, an oral soluble film formulation of ondansetron for the treatment of nausea and vomiting associated with chemotherapy and post-operative recovery; and Azstarys, a once-daily product for the treatment of attention deficit hyperactivity disorder.